about
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.The process defines the product: what really matters in biosimilar design and production?Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Biosimilars: Extrapolation for oncology
@ast
Biosimilars: Extrapolation for oncology
@en
Biosimilars: Extrapolation for oncology
@nl
type
label
Biosimilars: Extrapolation for oncology
@ast
Biosimilars: Extrapolation for oncology
@en
Biosimilars: Extrapolation for oncology
@nl
prefLabel
Biosimilars: Extrapolation for oncology
@ast
Biosimilars: Extrapolation for oncology
@en
Biosimilars: Extrapolation for oncology
@nl
P1476
Biosimilars: Extrapolation for oncology
@en
P2093
Ira Jacobs
Julie A Rosenberg
P304
P356
10.1016/J.CRITREVONC.2016.06.002
P407
P577
2016-06-15T00:00:00Z